Evidence map›GLP-1 receptor agonists × inflammation & biomarkers›PMID 28479155›Full record

SynthesisJournal of diabetes and its complications2017

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.

Mohsen Mazidi, Ehsan Karimi, Peyman Rezaie, Gordon A Ferns

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of diabetes and its complications, 2017. The graph read 1 number from its abstract, feeding 1 cell of the map: it supports the treatment in 1. It is linked to trial NCT04133922 (Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes), which is not on this map. Cited by 43 papers, 7 of them syntheses that pooled it.

1number the graph read from it
1cell of the map it votes in
43citing papers in PubMed, 7 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

← favours the treatmentfavours the comparator →
-3.510 · no effect
Serum CRP concentrationsGLP-1 RAs vs control (placebo or standard care, as implied by RCT context)favours the treatment · t2dfeeds one cell of the map
Δ -2.14-3.51 to -0.780.002
Heterogeneity was quantitatively assessed using the I RESULTS: Meta-analysis of the data from 7 treatment arms revealed a significant reduction in serum CRP concentrations following treatment with GLP-1 RAs (WMD -2.14 (mg/dL), 95% CI -3.51, -0.78, P=0.002; I CONCLUSIONS: This meta-analysis suggests that GLP-1 RAs therapy causes a significant reduction in CRP.
FeedsGLP-1 receptor agonists×inflammation & biomarkers

clause the extractor read what became the number

2 · Its place on the map

Where it lands on the map

Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.

supports the treatmentfavours the comparatorno clear differenceread, but no usable result
3 · What it changes

What it adds to each cell

For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.

GLP-1 receptor agonists×inflammation & biomarkers

SupportsOpen on the map →What to test next →

5 readable studies in this cell: 2 favour the treatment, 3 find no difference, 0 favour the comparator.

Belief with this paper
0.50contested · 2 families support, 1 contradict · against placebo
Without itNot a counted family in this claim, so removing it changes nothing.
← favours the treatmentfavours the comparator →
0 · no effect
NCT00781937422 enrolled · 2008
Treatment Contrast -13.0-23.4 to -2.64
NCT04019197108 enrolled · 2019
β coefficient -0.01-0.13 to 0.12
NCT0488111060 enrolled · 2021
Δ -0.40-0.70 to -0.07
NCT0062028249 enrolled · 2008
Least squares mean -0.42-1.12 to 0.28

This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.

4 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04133922 early_phase1withdrawnstarted 2019, after this paper: background citation

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Ran2019Enrolled0Registered outcomes5Posted comparisons0ConditionsInsulin Sensitivity/Resistance, Type 1 DiabetesArmsDextrose 20 % in Water, GLP-1, Insulin
PMID 27295427PMID 27436611PMID 15983263PMID 16567818PMID 17711996PMID 18612041PMID 1874938PMID 20739685PMID 21610226PMID 2189893PMID 23657563PMID 24658303other papers from this trial
Open the trial in the graph
5 · Its place in the literature

Who cites it

43 citing papers in PubMed, 7 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Article
  15. GLP-1 receptor agonists-another promising therapy for Alport syndrome?Journal of rare diseases (Berlin, Germany) · 2025
    Review
  16. Article
  17. Review
  18. Metaflammation in obesity and its therapeutic targeting.Science translational medicine · 2023
    Review
  19. Article
  20. Article
6 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

7 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Mohsen MazidiKey State Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China; Institute of Genetics and Developmental Biology, International College, University of Chinese Academy of Science, Beijing 100101, China. Electronic address: Moshen@genetics.ac.cn.
Ehsan KarimiBiochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
Peyman RezaieBiochemistry of Nutrition Research Center, School of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
Gordon A FernsDivision of Medical Education, Brighton and Sussex Medical School, Rm 342, Mayfield House, University of Brighton, Brighton BN1 9PH, United Kingdom.
Mashhad University of Medical Sciences · IRBrighton and Sussex Medical School · GBChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

8 · The paper itself

Abstract

The marked sentences are the ones the graph read a number from.

aimTo undertake a systematic review and meta-analysis of randomized controlled trials of the effect of glucagon-like peptide-1 receptor agonist (GLP-1 RAs) therapy on serum C-reactive protein (CRP) concentrations.

methodPubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched for the period up until March 16, 2016. Prospective studies evaluating the impact of GLP-1 RAs on serum CRP were identified. A random effects model (using the DerSimonian-Laird method) and generic inverse variance methods were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. Heterogeneity was quantitatively assessed using the I

resultsMeta-analysis of the data from 7 treatment arms revealed a significant reduction in serum CRP concentrations following treatment with GLP-1 RAs (WMD -2.14 (mg/dL), 95% CI -3.51, -0.78, P=0.002; I

conclusionsThis meta-analysis suggests that GLP-1 RAs therapy causes a significant reduction in CRP.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalBiomarkersC-Reactive ProteinDiabetes Mellitus, Type 2Down-RegulationExenatideGlucagon-Like Peptide-1 ReceptorGlycated HemoglobinHumansHyperglycemiaHypoglycemiaHypoglycemic AgentsLiraglutidePeptidesRandomized Controlled Trials as TopicVenomsAnti-Inflammatory Agents, Non-SteroidalBiomarkersC-Reactive ProteinExenatideGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsLiraglutidePeptidesVenomsC-reactive proteinGlucagon-like peptide-1 receptor agonistMeta-analysisRandomized controlled trialsType 2 diabetics

Identifiers

PMID28479155
OpenAlexW2414527615

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.